188 Chapter 8 outpatient population (COMETH study). Int J Cancer 2016; 138(4): 992-1002. 64. Luttmer R, De Strooper LM, Dijkstra MG, Berkhof J, Snijders PJ, Steenbergen RD, et al. FAM19A4 methylation analysis in selfsamples compared with cervical scrapes for detecting cervical (pre)cancer in HPVpositive women. Br J Cancer 2016; 115(5): 579-87. 65. Kelly H, Benavente Y, Pavon MA, De Sanjose S, Mayaud P, Lorincz AT. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. Br J Cancer 2019; 121(11): 954-65. 66. Salta S, Lobo J, Magalhães B, Henrique R, Jerónimo C. DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis. Clin Epigenetics 2023; 15(1): 125. 67. Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus cliniciancollected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screenpositive, non-inferiority trial. Lancet Oncol 2019; 20(2): 229-38. 68. Stanczuk G, Baxter G, Currie H, Lawrence J, Cuschieri K, Wilson A, et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and GallowayPaVDaG study). BMJ Open 2016; 6(4): e010660. 69. Arbyn M, Castle PE. Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program. Cancer Epidemiol Biomarkers Prev 2015; 24(5): 769-72. 70. Verhoef VM, Heideman DA, van Kemenade FJ, Rozendaal L, Bosgraaf RP, Hesselink AT, et al. Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. Gynecol Oncol 2014; 135(1): 58-63. 71. de Waard J, Bhattacharya A, de Boer MT, van Hemel BM, Esajas MD, Vermeulen KM, et al. Identification of a methylation panel as an alternative triage to detect CIN3+ in hrHPV-positive self-samples from the population-based cervical cancer screening programme. Clin Epigenetics 2023; 15(1): 103. 72. Chang CC, Huang RL, Liao YP, Su PH, Hsu YW, Wang HC, et al. Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. BMC Cancer 2015; 15: 418. 73. De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HME, van Kemenade FJ, et al. Validation of the FAM19A4/miR124-2 DNA methylation test for both lavage- and brush-based selfsamples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol 2016; 141(2): 341-7. 74. Klischke L, von Ehr J, Kohls F, Kampers J, Hülse F, Schmitz M, et al. Performance of a six-methylation-marker assay on selfcollected cervical samples - A feasibility study. J Virol Methods 2021; 295: 114219. 75. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018; 363: k4823. 76. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013; 17(5 Suppl 1): S28-35. 77. Vink FJ, Lissenberg-Witte BI, Meijer C, Berkhof J, van Kemenade FJ, Siebers AG, et al. FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive
RkJQdWJsaXNoZXIy MjY0ODMw